
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
CERo Therapeutics Holdings Inc (CEROW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CEROW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -83.33% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.43 | 52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.86% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 317536 |
Shares Outstanding - | Shares Floating 317536 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
CERo Therapeutics Holdings Inc
Company Overview
History and Background
CERo Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company was founded with the goal of harnessing the power of the body's immune system to fight cancer. Specific founding year and early milestones are currently not readily available.
Core Business Areas
- Cell Therapy Development: Developing cell-based immunotherapies, primarily focused on CAR-T cell therapies and other engineered cell therapies.
- Preclinical Research: Conducting preclinical research to identify and validate novel targets for cancer immunotherapy.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its lead product candidates in various cancer indications.
Leadership and Structure
Information regarding CERo Therapeutics Holdings Inc.'s specific leadership team and organizational structure is currently not readily available.
Top Products and Market Share
Key Offerings
- CER-123: A lead CAR-T cell therapy candidate targeting specific tumor antigens. Market share is not available due to its clinical stage. Competitors in CAR-T therapy include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).
- CER-456: Another CAR-T cell therapy candidate targeting specific tumor antigens. Market share is not available due to its clinical stage. Competitors in CAR-T therapy include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing substantial growth driven by advances in cell therapy, checkpoint inhibitors, and other innovative approaches. The competitive landscape is crowded with both large pharmaceutical companies and smaller biotechnology firms.
Positioning
CERo Therapeutics Holdings Inc. is positioned as an emerging player in the cell therapy space, focusing on developing novel CAR-T cell therapies. Competitive advantages depend on the differentiation and efficacy of their specific CAR-T candidates.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of dollars. CERo Therapeutics Holdings Inc.'s position within this TAM depends on the success of its clinical trials and commercialization efforts, but is currently a small portion.
Upturn SWOT Analysis
Strengths
- Novel CAR-T cell therapy candidates
- Focus on specific tumor antigens
- Potential for improved efficacy and safety compared to existing therapies
Weaknesses
- Early-stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in cell therapy technologies
Threats
- Competition from established players in the cell therapy market
- Regulatory hurdles
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
Competitive Landscape
CERo Therapeutics Holdings Inc. faces significant competition from established players with greater resources. Its success depends on demonstrating superior efficacy and safety in its clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's early stage.
Future Projections: Future projections depend heavily on the success of clinical trials and potential partnerships. Analyst estimates are not currently available.
Recent Initiatives: Recent initiatives likely involve advancing its lead CAR-T cell therapy candidates through clinical development.
Summary
CERo Therapeutics Holdings Inc. is a high-risk, high-reward clinical-stage company. Its success hinges on the development of its CAR-T cell therapy candidates. It needs to secure partnerships and financing while navigating a competitive landscape and regulatory hurdles. If its clinical trials have positive results, it is likely to be a good company in the sector, but it is only a small company that is in the clinical phase.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (when available)
- Industry Reports
- Analyst Reports (when available)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share percentages are approximated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-11-29 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.